Loading...
Some observers have suggested that diabetic patients might be more likely than nondiabetic patients to exhibit resistance to aspirin's antiplatelet effects. This issue was explored as part of the Johns Hopkins GeneSTAR study of families with early-onset coronary disease. Researchers performed platelet function testing in about 1900 nondiabetic and 200 diabetic people who had no personal history of coronary disease but were close relatives of patients who had documented adverse coronary events before age 60. Testing was done before and immediately after a 2-week course of aspirin (81 mg daily).
On in vivo testing, diabetic participants showed higher platelet activation than did nondiabetic participants, but aspirin reduced platelet activation…